177 related articles for article (PubMed ID: 15897553)
1. The pathway to biomarker discovery: carbonic anhydrase IX and the prediction of immune responsiveness.
Panelli MC; Wang E; Marincola FM
Clin Cancer Res; 2005 May; 11(10):3601-3. PubMed ID: 15897553
[No Abstract] [Full Text] [Related]
2. Carbonic anhydrase IX as a predictive biomarker of response to kidney cancer therapy.
Signoretti S; Regan M; Atkins M
BJU Int; 2008 Jun; 101 Suppl 4():31-5. PubMed ID: 18430120
[No Abstract] [Full Text] [Related]
3. Carbonic anhydrase IX/G250/MN: a molecule too good to be true?
Oosterwijk E
BJU Int; 2008 Mar; 101(5):527-8. PubMed ID: 18257853
[No Abstract] [Full Text] [Related]
4. CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis.
de Martino M; Klatte T; Seligson DB; LaRochelle J; Shuch B; Caliliw R; Li Z; Kabbinavar FF; Pantuck AJ; Belldegrun AS
J Urol; 2009 Aug; 182(2):728-34. PubMed ID: 19539328
[TBL] [Abstract][Full Text] [Related]
5. Carbonic anhydrase IX and renal cell carcinoma: prognosis, response to systemic therapy, and future vaccine strategies.
Shuch B; Li Z; Belldegrun AS
BJU Int; 2008 Jun; 101 Suppl 4():25-30. PubMed ID: 18430119
[No Abstract] [Full Text] [Related]
6. Immunohistochemical expression of carbonic anhydrase IX assessed over time and during treatment in renal cell carcinoma.
Jensen HK; Nordsmark M; Donskov F; Marcussen N; von der Maase H
BJU Int; 2008 Jun; 101 Suppl 4():41-4. PubMed ID: 18430123
[No Abstract] [Full Text] [Related]
7. Target-specific therapy requires target-specific populations in the treatment of renal cell carcinoma.
Figlin RA; Alvin H; Meinhardt CL
Urologe A; 2004 Sep; 43 Suppl 3():S144-5. PubMed ID: 15179554
[No Abstract] [Full Text] [Related]
8. In vivo molecular prediction of carbonic anhydrase IX-G250MN expression on immunotherapy outcome in renal cancer.
Brouwers AH; Boerman OC; Oyen WJ
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8886; author reply 8886. PubMed ID: 16361579
[No Abstract] [Full Text] [Related]
9. Specific monoclonal antibody-based immunotherapy by targeting the RCC-associated antigen carbonic anhydrase-IX(G250/MN).
Mulders P; Bleumer I; Debruyne F; Oosterwijk E
Urologe A; 2004 Sep; 43 Suppl 3():S146-7. PubMed ID: 15164181
[No Abstract] [Full Text] [Related]
10. Carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer.
Stewart GD; O'Mahony FC; Laird A; Rashid S; Martin SA; Eory L; Lubbock AL; Nanda J; O'Donnell M; Mackay A; Mullen P; McNeill SA; Riddick AC; Aitchison M; Berney D; Bex A; Overton IM; Harrison DJ; Powles T
Eur Urol; 2014 Nov; 66(5):956-63. PubMed ID: 24821582
[TBL] [Abstract][Full Text] [Related]
11. Molecular markers to predict response to therapy.
Garcia-Donas J; Rodriguez-Antona C; Jonasch E
Semin Oncol; 2013 Aug; 40(4):444-58. PubMed ID: 23972708
[TBL] [Abstract][Full Text] [Related]
12. Methylation of the CA9 promoter can modulate expression of the tumor-associated carbonic anhydrase IX in dense carcinoma cell lines.
Jakubicková L; Biesová Z; Pastoreková S; Kettmann R; Pastorek J
Int J Oncol; 2005 Apr; 26(4):1121-7. PubMed ID: 15754010
[TBL] [Abstract][Full Text] [Related]
13. Carbonic Anhydrase IX in Renal Cell Carcinoma, Implications for Disease Management.
Courcier J; de la Taille A; Nourieh M; Leguerney I; Lassau N; Ingels A
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32998233
[TBL] [Abstract][Full Text] [Related]
14. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.
Atkins M; Regan M; McDermott D; Mier J; Stanbridge E; Youmans A; Febbo P; Upton M; Lechpammer M; Signoretti S
Clin Cancer Res; 2005 May; 11(10):3714-21. PubMed ID: 15897568
[TBL] [Abstract][Full Text] [Related]
15. Carbonic anhydrase 9 in clear cell renal cell carcinoma: a marker for diagnosis, prognosis and treatment.
Tostain J; Li G; Gentil-Perret A; Gigante M
Eur J Cancer; 2010 Dec; 46(18):3141-8. PubMed ID: 20709527
[TBL] [Abstract][Full Text] [Related]
16. Carbonic anhydrase IX as a predictive biomarker for clear cell renal cell carcinoma.
Pantuck AJ; Klatte T; Seligson D; Atkins M; Belldegrun A
J Clin Oncol; 2008 Jun; 26(18):3105-7; author reply 3107-9. PubMed ID: 18565906
[No Abstract] [Full Text] [Related]
17. Carbon anhydrase IX specific immune responses in patients with metastatic renal cell carcinoma potentially cured by interleukin-2 based immunotherapy.
Rasmussen S; Donskov F; Pedersen JW; Wandall HH; Buus S; Harndahl M; Braendstrup P; Claesson MH; Pedersen AE
Immunopharmacol Immunotoxicol; 2013 Aug; 35(4):487-96. PubMed ID: 23802595
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer.
Potter CP; Harris AL
Br J Cancer; 2003 Jul; 89(1):2-7. PubMed ID: 12838292
[TBL] [Abstract][Full Text] [Related]
19. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma.
Cho D; Signoretti S; Dabora S; Regan M; Seeley A; Mariotti M; Youmans A; Polivy A; Mandato L; McDermott D; Stanbridge E; Atkins M
Clin Genitourin Cancer; 2007 Sep; 5(6):379-85. PubMed ID: 17956710
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapeutic strategies in kidney cancer--when TKIs are not enough.
Biswas S; Eisen T
Nat Rev Clin Oncol; 2009 Aug; 6(8):478-87. PubMed ID: 19546865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
